ROIV Stock: Price, Earnings History and SEC Filings
Roivant Sciences Ltd. (ROIV) last traded at $36.91, down 1.63% on the latest session and up 0.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.45 against an analyst estimate of $-0.45, a beat of 0.0%.
$36.91 -1.63%
1 month+0.93%
52-week high$42.50
52-week low$19.30
Volume4.57M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ROIV earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.45 | $-0.45 | +0.00% |
| Mar 2026 | May 20, 2026 | $-0.46 | $-0.38 | -21.05% |
| Dec 2025 | Feb 6, 2026 | $-0.36 | $-0.39 | +7.69% |
| Sep 2025 | Nov 10, 2025 | $-0.40 | $-0.34 | -17.65% |
ROIV beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ROIV
SEC filing data is not available right now. You can search for ROIV on SEC EDGAR.
ROIV news
- Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy GiftOct 29, 2026 · finance.yahoo.com
- Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis TrialsOct 23, 2026 · tikr.com
- Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis ResultsOct 21, 2026 · marketbeat.com
- Roivant Sciences stock surges on positive uveitis trial dataOct 21, 2026 · finance.yahoo.com
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026Oct 21, 2026 · finance.yahoo.com
- Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026Oct 21, 2026 · finance.yahoo.com
- Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)Oct 21, 2026 · finance.yahoo.com
About Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) is a US-listed public company on Nasdaq.